Stimulating Targeted Antigenic Responses To NSCLC
Learn More About This Topic: Chat with Us | Email Us
START - Stimulating Targeted Antigenic Responses To NSCLC A multicentre, randomised, double-blind, placebo-controlled, phase III study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in patients with non-small cell lung cancer (NSCLC) with non- resectable stage III disease
Summary
You are being asked to take part in this research study because you have a non-small cell lung cancer. The purpose of this research study is to find out whether taking a new cancer treatment called Stimuvax (or L-BLP25 or BLP25 liposome vaccine) in addition to best supportive care can extend your life and provide you with a good quality of life.
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.
